RPL17 and early-onset autosomal dominant Alzheimer disease: This is followed by “PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer’s disease,” which indicates that immune checkpoint blockade is a novel therapeutic strategy for AD and, potentially, for other neurodegenerative diseases.